Clinical trials: Hyperemia
Ocular Hyperemia
Efficacy and Safety of FID 123472 Ophthalmic Solution for Ocular Redness in Adults
The purpose of this study is to evaluate the efficacy and safety of an investigational ophthalmic solution in adults with ocular redness due to minor eye irritations.
- Trial name
- NCT07531043
- Testing
- Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Free, Vehicle
- Where
- 9 sites in United States
- Volunteers
- 230 people
- Sponsor
- Alcon Research
Ocular Hyperemia
An Investigation of FID 123472 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness in Adults
The purpose of this study is to evaluate the efficacy and safety of an investigational ophthalmic solution in adults with ocular redness caused by minor eye irritations.
- Trial name
- NCT07578363
- Testing
- Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Free, Vehicle
- Where
- 5 sites in United States
- Volunteers
- 178 people
- Sponsor
- Alcon Research
Heart Failure, Chronic Heart Failure
Wearable Tissue Oximetry During Arm Cuff Occlusion, Walking, and Standing Tests in Outpatients With Chronic Heart Failure
This prospective, single-center, observational pilot study evaluated an investigational wearable tissue oximeter (NIRSense Argus Oximetry System, also called Envello Core) in adult outpatients with chronic heart failure in New…
- Trial name
- NCT07874386
- Testing
- Argus Oximetry System
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- NIRSense Inc.
Hyperemia Eye
Safety and Tolerability of PRO-185
Phase I Study to evaluate safety and tolerability of PRO-185 (naphazoline/hypromellose) ophthalmic solution through evaluation of vital signs, ocular signs such as intraocular pressure, hyperemia and mydriasis and adverse events.
- Trial name
- PRO-185 (NCT05470868)
- Testing
- Naphazoline / Hypromellose Ophthalmic
- Where
- Mexico
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Laboratorios Sophia S.A de C.V.
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease.
- Trial name
- STRIDE 1 (NCT02813265)
- Testing
- KPI-121 0.25% Ophthalmic Suspension, Vehicle of KPI-121 0.25% Ophthalmic Suspension
- Where
- 60 sites in United States
- Volunteers
- 918 people
- Sponsor
- Kala Pharmaceuticals, Inc.
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease.
- Trial name
- Kauai (NCT02188160)
- Testing
- KPI-121
- Where
- 11 sites in United States
- Volunteers
- 150 people
- Sponsor
- Kala Pharmaceuticals, Inc.
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease
The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease.
- Trial name
- STRIDE 2 (NCT02819284)
- Testing
- KPI-121 0.25% Ophthalmic Suspension, Vehicle of KPI-121 0.25% Ophthalmic Suspension
- Where
- 62 sites in United States
- Volunteers
- 909 people
- Sponsor
- Kala Pharmaceuticals, Inc.
Pterygium
A Study of the Response to AG-86893 in Patients With Pterygium Hyperemia
A pterygium is a wing-shaped, benign tissue growth which forms on the surface of the conjunctiva and grows towards the cornea. It can eventually lead to vision impairment.
- Trial name
- SURPH (NCT03533244)
- Testing
- 0.1% AG-86893 Eye Drops, 0.3% AG-86893 Eye Drops, Vehicle Eye Drops
- Where
- 6 sites in Australia
- Volunteers
- 64 people
- Sponsor
- Allgenesis Biotherapeutics Inc.
Hyperemia
Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Participants With Ocular Redness
To compare the efficacy and safety of brimonidine tartrate ophthalmic solution 0.025% with its vehicle for the treatment of ocular redness in a population of adult and geriatric participants with ocular redness.
- Trial name
- NCT01959230
- Testing
- Brimonidine Tartrate, Vehicle, Sodium Fluorescein
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Bausch & Lomb Incorporated
Hyperemia
Safety of Brimonidine Tartrate Ophthalmic Solution in a Population of Pediatric, Adult, and Geriatric Participants
To compare the safety and tolerability of brimonidine tartrate ophthalmic solution 0.025% versus its vehicle in a population of pediatric, adult, and geriatric participants.
- Trial name
- NCT01959243
- Testing
- Brimonidine Tartrate, Vehicle, Sodium Fluorescein
- Where
- 4 sites in United States
- Volunteers
- 507 people, healthy volunteers welcome
- Sponsor
- Bausch & Lomb Incorporated
Hyperemia
Pharmacokinetics and Safety of Topical Administration of Brimonidine Tartrate Ophthalmic Solution 0.025%.
To characterize the plasma pharmacokinetics and safety profile of brimonidine following a single dose and 4 times per day (QID) dosing of brimonidine tartrate ophthalmic solution 0.025% for 7 days in healthy, adult subjects.
- Trial name
- NCT02039765
- Testing
- Brimonidine tartrate
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Bausch & Lomb Incorporated